Viewing Study NCT03260894


Ignite Creation Date: 2025-12-25 @ 1:34 AM
Ignite Modification Date: 2026-02-01 @ 11:16 PM
Study NCT ID: NCT03260894
Status: COMPLETED
Last Update Posted: 2025-07-29
First Post: 2017-08-22
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Sponsor: Incyte Corporation
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Renal Cell Carcinoma (RCC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Renal cell carcinoma View
None programmed cell death 1 (PD-1) inhibitor View
None indoleamine 2 View
None 3-dioxygenase 1 (IDO1) inhibitor View